Phathom Pharmaceuticals reported second quarter 2026 financial results with net revenues of $74.3 million, an 88% increase year-over-year and a record for the period. The company achieved operating profitability excluding stock-based compensation, with total operating expenses reduced by 33% to $63.1 million compared to Q2 2025. Net loss narrowed significantly to $17.6 million from $75.8 million in the prior year quarter. Cash and cash equivalents stood at $182.5 million as of June 30, 2026. The company updated its full-year 2026 net revenue guidance downward to a range of $310–$325 million from the previous $320–$345 million estimate. Additionally, Phathom announced plans to initiate a Phase 3 clinical trial for as-needed dosing of VOQUEZNA in Non-Erosive GERD patients and reported completion of enrollment in its Phase 2 Eosinophilic Esophagitis trial. Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases.

Phathom Pharmaceuticals, Inc. announced the completion of patient enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which evaluates VOQUEZNA (vonoprazan) for the treatment of eosinophilic esophagitis (EoE) in adults. The randomized, double-blind, placebo-controlled study has enrolled 95 patients across 41 U.S. sites, with topline results expected in the fourth quarter of 2026. Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing gastrointestinal treatments.